Daily Alpha · Reddit
· Post-Market Alpha · by Buzzberg Research
Company debates distinguish operating progress from financing risk, acquired growth from organic performance and low multiples from durable cash returns. Kodiak’s dated unlock and TSH’s acknowledged illiquidity are concrete ownership constraints.
Themes on this desk
Fed reaction
A September 16 recap reports the initial announcement rally reversing during the press conference. Its sequence does not establish a single cause or make reposts independent confirmations.
Benchmark versus deployment
Nvidia’s cited MLPerf preview reports up to 3.7 times GB300 throughput; a separate cluster-reporting framework distinguishes hardware delivery from workload validation and production scope.
Financing and AI buildout
An AMD discussion recommends hedging large high-beta gains and argues more expensive private borrowing could slow AI buildout. This is a proposed response, without an executed hedge.
Highest engagement
by score · day changeKodiak lockup and financing needs are reported as near-term supply risks
The writer says the September 24–25 lockup expiry could release roughly 88 million shares into a float of about 112 million, and cites $151 million of cash against about $160 million annual burn. A future raise is the writer's expectation, rather than an already completed financing or proof that all unlocked shares will be sold.
**1. The lockup expires September 24-25.** Roughly 88M shares come free into a float of about 112M.
The reported unlock and cash-burn comparison could create supply and financing pressure even if the operating thesis progresses; actual selling and financing terms would determine its severity.
Watch Lockup-related share availability and selling, updated cash and burn disclosures, and the timing and terms of any announced financing.
Source →A DXYZ thesis links a reported NAV discount to a conditional Anthropic rerating
The post cites a last reported DXYZ NAV of $34.30 per share versus a stock price around $30, and says Anthropic represented about 14.4% of NAV at June 30, worth roughly $236 million. A possible $2 trillion Anthropic IPO valuation is presented as a reported possibility supporting a conditional NAV-rerating thesis, rather than a completed IPO or assured premium.
This makes for a fantastic entry level. At June 30, Anthropic was ~14.4% of DXYZ NAV, worth roughly $236M.
Future portfolio valuation marks and DXYZ's market discount would determine how the proposed private-company rerating translates into the fund's share price; the rumored IPO alone would not establish a realized gain.
Watch Updated DXYZ NAV and holdings marks, actual Anthropic financing or filing disclosures, and whether the market discount narrows or persists.
Source →A Xerox fund reportedly expands ownership and presses for an XFS review
The post says STARTEEPO increased common shares from 6.6 million through 8.0 and 8.8 million to 9.5 million, with 7.23% common ownership and 7.34% beneficial ownership including options. It reports requests to Xerox's board for XFS transparency, a strategic review and continued deleveraging; the board is not established as having acted.
**7.23% common ownership** and **7.34% beneficial ownership including options.** But the bigger development is that this is no longer just
The reported combination of increased ownership and specific board requests makes a potential corporate catalyst testable, while the board's discretion leaves implementation uncertain.
Watch Subsequent ownership disclosures and any Xerox board response or formally announced XFS review.
Source →Gloo bull case explicitly flags acquisition-driven growth as the key risk
The same author concedes a lot of GLOO's growth has come from acquisitions and that if organic growth disappoints 'this gets ugly,' while noting analyst targets as high as $17/share.
The obvious risk is that a lot of the growth has come from acquisitions.
The bull case is contingent on integration and organic growth; a miss there would invalidate the cheap-multiple argument quickly.
Watch Disclosure of organic versus inorganic revenue contribution in the next report, and whether analyst targets hold after that print.
Source →DXC bear points: sub-2% operating margins, ROIC below cost of capital
The DXC write-up notes revenue has drifted down as legacy contracts roll off, operating margins sit under two percent, the company carries meaningful long-term debt against a modest cash pile, and ROIC lags cost of capital.
at under two percent. Financially speaking, things are a bit delicate.
Cheapness on paper coexists with weak returns on capital, the classic condition for a value trap rather than a re-rating.
Watch Operating margin trajectory and any evidence ROIC is closing the gap to cost of capital.
Source →Most argued
by comments per upvoteONGC lags crude rally on HPCL drag and windfall tax risk
A post argues ONGC has not responded to crude near multi-year highs because its HPCL stake drags consolidated earnings when marketing margins compress, frequent windfall-tax reviews create a valuation overhang, production growth remains weak, and a PSU discount persists.
ONGC owns HPCL, and when crude spikes sharply, OMCs can suffer if retail fuel prices don't move in line.
Upstream oil exposure is not a clean crude proxy when integrated downstream assets and policy risk dilute the earnings transmission.
Watch Whether ONGC's consolidated earnings and share price diverge from crude if HPCL margins stay pressured or the windfall tax is revised.
Source →The Singapore TSH thesis acknowledges a tiny illiquid stock and just-above-20% float
The writer describes TSH Corporation in Singapore as illiquid, with a float just above 20% and an S$6.39 million market capitalization, and says it is suitable only for a personal account. Those liquidity limitations accompany the valuation thesis, without establishing an easy institutional-size exit.
way. He has also been repeatedly buying shares in the open market.
A quoted valuation discount may be difficult to realize if position entry or exit is constrained by the explicitly acknowledged small float and liquidity.
Watch Trading liquidity, spread and achievable transaction size alongside current float and market-capitalization disclosures.
Source →Inventiva's NATiV3 phase 3 readout remains a prospective Q4 2026 catalyst
The writer says NATiV3 phase 3 results are expected in Q4 2026 and reports management maintaining Q4 guidance. The roughly 18% placebo-adjusted fibrosis benefit is cited as a prior phase 2b result to reproduce; the upcoming phase 3 outcome and potential GLP-1 combination are not demonstrated results.
Q4 2026. Guggenheim maintains its Buy rating and raised its price target from $11 to $14.
The stated quarter provides a falsifiable catalyst window, while the earlier trial result and potential combination cannot establish phase 3 success or approval.
Watch The actual readout date, composite primary endpoint and phase 3 results compared with the cited prior-trial benefit and Q4 guidance.
Source →